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Abstract
The healing of the intestine is becoming an important objective in themanagement of inflammatory
bowel diseases. It is associated with improved disease outcome. Therefore the assessment of this
healing both in clinical studies and routine practice is a key issue. Endoscopy for the colon and
terminal ileum and computerized tomography or magnetic resonance imaging for the small bowel
are the most direct ways to evaluate intestinal healing. However, there are many unsolved
questions about the definition and the precise assessment of intestinal healing using these
endoscopic and imaging techniques. Furthermore, these are relatively invasive and expensive
procedures that may be inadequate for regular patients' monitoring. Therefore, biomarkers such ase Gastroenterologie, CHU de Liège, Domaine du Sart Tilman 4000 Liège, Belgium.
ac.be (E. Louis).
1 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
485Imaging and biomarkers assessing intestinal healing in IBDC-reactive protein and fecal calprotectin have been proposed as surrogate markers for intestinal
healing. Nevertheless, the sensitivity and specificity of these markers for the prediction of healing
may be insufficient for routine practice. New stool, blood or intestinal biomarkers are currently
studied and may improve our ability to monitor intestinal healing in the future.
© 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.Contents
1. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 485
2. How to define mucosal healing in Crohn's disease? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 485
3. How to define mucosal healing in Ulcerative colitis? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 487
4. How to define transmural healing in Crohn's disease? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 487
5. How to assess fistulae and strictures in Crohn's disease (pathological healing)? . . . . . . . . . . . . . . . . . . . . . 488
5.1. Stricturing disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 488
5.2. Definition of stricture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 489
5.3. Radiological techniques for the detection of strictures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 489
5.4. Comparison between radiological techniques . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 489
5.5. Differentiation between fibrotic and inflammatory strictures . . . . . . . . . . . . . . . . . . . . . . . . . . 489
5.6. Penetrating disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 489
6. Are serologic and genetic markers associated with tissue healing? . . . . . . . . . . . . . . . . . . . . . . . . . . . . 490
6.1. Genetic markers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 490
6.2. Serologic markers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 490
7. What is the role of stool markers in the assessment of mucosal healing? . . . . . . . . . . . . . . . . . . . . . . . 491
8. What is the role of blood markers in the assessment of mucosal healing? . . . . . . . . . . . . . . . . . . . . . . . 492
9. Are there alternative biomarkers of interest?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 492
Conflict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 493
Aknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 493
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4931. Introduction
In February 2010 the SciCom launched its second pathogen-
esis workshop: “Relevance of Intestinal Healing for the
Disease Course of IBD”. In four different expert groups, the
current knowledge about Mechanisms of Intestinal Healing
(Basic science), Measures and Markers of Prediction to
achieve, detect, and monitor Intestinal Healing, Impact of
Intestinal Healing on the Course of IBD (Natural history), and
Therapeutic Strategies to enhance Intestinal Healing (Ther-
apy) was gathered and areas of future research identified.
This manuscript summarized the results from the working
group on Measures and Markers of Prediction to achieve,
detect, and monitor Intestinal Healing, namely the assess-
ment of Intestinal healing in inflammatory bowel disease
using imaging techniques and biomarkers.
The assessment of tissue healing has become of para-
mount importance in inflammatory bowel disease. Simple
clinical assessment does not reflect real activity and
inflammation at the tissue level. Moreover, cumulative
tissue damage generated by this persisting tissue inflamma-
tion leads to non reversible anatomic and functional
consequences. Therefore, to evaluate both the natural
history and impact of treatment in inflammatory bowel
disease, standardized assessment of tissue healing must be
available. To define the current situation and propose areas
for future research, the working group of the second ECCO
workshop on assessment of tissue healing in inflammatorybowel disease using imaging techniques and biomarkers, has
addressed seven specific questions. These questions concern
the definition of mucosal healing in Crohn's disease (CD) and
ulcerative colitis (UC), the assessment of transmural and
pathological healing in CD, the association with serologic and
genetic markers, and the potential role of blood, stool and
alternative biomarkers.2. How to define mucosal healing in Crohn's
disease?
Endoscopic activity may reliably be scored with one of the
validated endoscopic activity scores, either the Crohn's
disease endoscopic index of severity (CDEIS)1 or the simple
endoscopic score for Crohn's disease (SES-CD)2; both scores
were shown to be highly reproducible (excellent inter-
observer agreement was demonstrated) and they were
prospectively validated.1–3 Nonetheless both scores are
rather complicated, therefore their use is restricted to
clinical trials and is uncommon in routine clinical practice.
Another very widely used score is the Rutgeerts' score for
grading post-surgical recurrence severity. Rutgeerts's score
was developed and validated1,4,5 in order to predict a
relevant difference in prognosis in the post-surgical setting.
Although the score lacks formal evaluation of inter-observer
agreement, it has been widely used across many different
clinical trials and clinical series, and its prognostic value was
486 M. Daperno et al.confirmed.6–9 The main characteristics, strengths and
weaknesses of these score are shown in Table 1.
With respect to endoscopic healing, it should be kept in
mind that CDEIS1 and SES-CD2 were developed in order to
transform the level of endoscopic activity of CD into a
continuous variable, but not to predict relevant difference in
prognosis, nor to determine cut-off values for endoscopic
remission or for different levels of endoscopic activity. Their
intrinsic complexity, together with the absence of validated
score thresholds associatedwith specific prognostic values and
with endoscopic healing, are the major weaknesses of these
scores. Attempts to define endoscopic remission or minimal
activity led to identification of CDEIS cut-off of lower than 3
points10,11 and of SES-CD cut-off of lower than 5 points,12
although in other studies the best prognosis seemed to be
associated with a CDEIS or SES-CD scores of 0 points.11,13
Currently available definitions of endoscopic healing thatwere
associated with better clinical outcome (including less clinical
relapses, surgical procedures and hospitalization) are thus
multiple and heterogeneous: no mucosal ulceration observed
in any of the 5 segments by endoscopy,14 disappearance of all
ulcerative lesions,13,15 absence ofmucosal ulceration,16 CDEIS
≤2,11 SES-CD ≤5, a Rutgeerts' score equal or lower than i1.5–
9,17,18 Variations in endoscopic scores were also used in post-
hoc analyses of the EXTEND trial. A difference in prognosis
for those patients attaining a more pronounced decrease in
endoscopic activity was observed,19 but they need further and
prospective validation.
Although theoretically appealing, the prognostic relevance
of histological healing has not been studied. Particularly, it is
currently unknown whether histological healing can be
achieved with current drugs in CD and what is its impact on
disease outcome. Assessment and definition of mucosal
healing in areas of the gastro-intestinal tract that cannot beTable 1 Strengths and weaknesses of the more frequently used
IBD score Endoscopic variables Stren
Endoscopic score for CD
CDEIS Deep ulceration, superficial
ulceration, extent of ulcerated
and affected surface, and
narrowing
Gold
asses
seve
repr
SES-CD Size of ulcers, extent of ulcerated
and affected surface, and narrowing
Simp
Rutgeerts score Aphtoid lesions, inflammation,
ulcers, nodules, and narrowing
Gold
of po
valid
pred
Endoscopic score for UC
Mayo endoscopic
subscore
Erythema, vascular pattern, friability,
bleeding, erosions, and ulcerations
Easy
Muco
score
Rachmilewitz
endoscopic index
Granulation, vascular pattern,
vulnerability of mucosa, and mucosal
damage (mucus, fibrin, exudate,
erosions, ulcer)
Used
repr
Modified Baron score Friability, vascular pattern,
bleeding, and ulceration
Easyreached by conventional endoscopy are also much less clearly
documented. There are no published data on jejunal and
proximal ileal lesion healing assessed with capsule endoscopy
or with other device-assisted enteroscopy and there is no
validated scoring system to assess small bowel endoscopic
activity. However, current ECCO guidelines on small bowel
endoscopy20 report that small bowel capsule endoscopy has a
potential role in the assessment of mucosal healing of lesions
based on a small trial.21 Other imaging techniques (ultrasound
(US), magnetic resonance imaging (MRI)) may depict ameliora-
tion of the bowel wall pattern (thinner wall, better stratifica-
tion, reduction of mesenteric fat proliferation, reduction in
bowel wall enhancement, disappearance of edema) up to
complete normalization of the bowel wall. Several serial MRI
studies are available in the literature analyzing the pattern of
fistula healing,22–25 but no large quality data is available on the
issue of luminal disease, especially with respect to response to
medical treatment and prognostic impact,26–30 and data on
correlations between endoscopy and US/MRI are few.31,32
Key messages
• Endoscopic activity may be reliably scored in different clinical
conditions:
– Crohn's disease endoscopic index of severity (CDEIS) or simple
endoscopic score for Crohn's disease (SES-CD) for luminal CD
– Rutgeerts' score for anastomotic post-surgical recurrence of
disease
• Composite indices are seldom used in clinical practice due to
their complexity, while Rutgeerts' score use may be advocated
routinely
• Endoscopic healing (EH) is commonly defined as the disappearance
of all ulcerative lesions, although slightly different definitionswere
used in different studiesendoscopic diseases activity scores in IBD.
gths Weaknesses
standard for endoscopic
sment of CD, used in
ral clinical studies,
oducible
Complex for routine use in
clinical practice. No well
validated definition of mucosal
healing
lified score for CD No validated definition of
mucosal healing
standard for the assessment
stoperative disease recurrence,
ated cut-off value for the
iction of clinical relapse
Can be used only in operated
patients for assessment of
postoperative recurrence
to use, 4-point scale (0–3).
sal healing defined by a
of 0 or 1
Not enough accurate, no
discrimination between
superficial and deep ulceration
in many clinical studies,
oducible
No validated definition of
mucosal healing
to use, 5-point scale (0–4) No discrimination between
superficial and deep ulceration
487Imaging and biomarkers assessing intestinal healing in IBD• Degrees of endoscopic amelioration impacting on disease
outcome were studied, and several thresholds in endoscopic
scores were proposed (CDEIS=0/≤3/≤6, SES-CD=0/≤5)
Areas for future research
• Formal evaluation of inter-observer agreement for endoscopic
scores of activity
• Larger trials with endoscopic healing as primary endpoint and
relevant prognostic outcomes
• Development and validation of meaningful endoscopic response
criteria with CDEIS/SES-CD as well as with more simple criteria
for routine practice
• Optimal assessment of mucosal healing in the small bowel using
small bowel capsule endoscopy and/or imaging techniques.
3. How to define mucosal healing in Ulcerative
colitis?
Truelove and Witts were the first to report on the sigmoido-
scopic appearance of the gut mucosa during a placebo-
controlled trial of cortisone for the treatment of active disease.
Endoscopic lesions were classified as normal or near normal
(slight hyperemia or granularity as only abnormal finding),
improved, or no change or worse.33 Thereafter, several
endoscopic scoring systems were developed using different
items and definitions of mucosal healing. The Baron score34 and
the Powell-Tuck sigmoidoscopic assessment35 focus on the
assessment of severity of bleeding without considering ulcers or
other mucosal changes. The Baron score, distinguishing three
grades of activity,was commonly used to evaluate the degree of
activity endoscopically. The most commonly used is the
endoscopic component of the Mayo score.36 Schroeder et al.
performed serial flexible proctosigmoidoscopic assessments
during a placebo-controlled trial of oral delayed release
mesalamine for the treatment of UC. The appearance of the
rectal mucosa was described using a 4-point scale (0–3) andwas
called the Mayo score.36 Currently, the Mayo score is preferred
in clinical studies. When using the Mayo endoscopic subscore,
mucosal healing is defined as a score drop toMayo score of 0 or 1
(Mayo 0 = normal or inactive disease andMayo 1 =mild disease—
erythema, decreased vascular pattern, mild friability). These
criteria were used in several clinical trials.37–43 However amore
recent recommendation of the Food and Drug Administration is
to consider any friability as non-healed mucosa. The Mayo score
does not distinguishdeepulcers fromsuperficial ulcers and is not
useful for the evaluation of severe colitis. The score reproduc-
ibility was formally evaluated in a prospective study44 which
outlined that adequate reproducibility in the score application
was achieved only for expert endoscopists. Rachmilewitz
performed serial endoscopic assessments during a controlled
comparison of coated mesalamine and sulfasalazine for the
treatment of active UC.45 In this trial, an instrument consisting
of four items was described: granulation scattering reflected
light, vascular pattern, vulnerability of mucosa, and mucosal
damage (mucus, fibrin, exudates, erosions, and ulcer). Scores
range from 0 to 12 points. Endoscopic remission was defined as
an endoscopic index score of 0–4 points. The instrument has not
yet been validated. Feagan et al.46 performed serial endoscopic
assessments during a placebo-controlled trial of anti-α4 β7
integrin antibody (MLN-02) for active UC, describing endoscopic
activity on a 5-point scale (0–4).With thismodified Baron Score,endoscopic remission was defined as a Score of 0. Endoscopic
response was defined as an improvement of the Modified Baron
Score of at least two grades from baseline. Neither the Modified
Baron Score nor the definitions of endoscopic remission or
endoscopic responsehavebeen validated.The reproducibility of
scoring individual lesions and overall severity resulted good-to-
excellent in a more recent study.47 This study proposed a new,
more detailed and complicated endoscopic score, named
ulcerative colitis endoscopic index of severity (UCEIS), that
has been formally validated but is only published in abstract
format.48 The strengths and weaknesses of the more frequently
used endoscopic diseases activity scores in UC are presented in
Table 1.
The risks of relapse or colectomy are important clinical
outcomes, and seem to be reduced by attaining mucosal
healing.49,50 However studies specifically aimed at analyzing
risk factors for disease relapse generally considered active
endoscopic picture as an exclusion criterion. Nevertheless, a
small trial published only as abstract51 demonstrated that
patients in clinical remission with endoscopic activity grade
Mayo 2–3 had a substantially higher risk of clinical relapse as
compared to those with endoscopic activity grade Mayo 0–1,
after a course of mesalamine. More recently52 it was shown
that patients attaining clinical remission but with remaining
signs of endoscopic activity (about one quarter of patients
after a steroid course) had significantly higher risks of
adverse outcomes and colectomy, with odd ratios ranging
from 2 to more than 6 for different outcomes. The goal of
reaching substantial endoscopic healing in ulcerative colitis
is also supported by its protective effects on UC-related
cancer incidence.53 The same study supported an even
greater importance of histological inflammation in the risk of
colorectal cancer development in ulcerative colitis, with odd
ratios between 4.7 and more than 6.
Key messages
• The most commonly used endoscopic activity score is the Mayo
endoscopic score, with the commonly accepted criterion for
endoscopic healing being Mayo grade 0 or 1(although any
friability should be considered as non healed mucosa)
• Mucosal healing substantially reduces the risks of both clinical
relapse and surgery
• There is a potential relationship between endoscopic healing and
cancer risk reduction
• Histological healing appears to be preferable for cancer
prevention, but limited data on its scoring are available
• Relevance of histological healing on disease recurrence is
uncertain
Areas for future research
• Further evaluation of agreement for Mayo score and generation
of more reproducible scoring systems
• Relevance and interpretation of heterogeneous severity of the
endoscopic activity along the colon
• Definition and evaluation of prognostic value of histological
healing in ulcerative colitis.
4. How to define transmural healing in Crohn's
disease?
Eradication of inflammation in all the layers of the bowel
wall would be a logical goal of treatment. It has been
488 M. Daperno et al.suggested54 that mucosal healing may be a minimal
therapeutic goal in CD, as in the presence of a pathologic
process characterized by transmural inflammation, healing
of the most superficial layer only seems to be too little and
too partial. There are, however, no published studies in
which transmural healing was used as the major therapeutic
endpoint of a CD patient treatment, while mucosal healing is
becoming more and more a therapeutic goal.10,13,15,16,55
Therefore any recommendation to use transmural healing as a
treatment endpoint, although logical, is not evidence-based.
In a recent study56 comparing colonoscopy and PET-CT,
only 35 out of 56 intestinal segments highlighted by 18F-2-
deoxyfluoroglucose (18F-FDG) had detectable mucosal lesions
at colonoscopy. Although these segments could have been a
false positive for FDG uptake, the presence of wall thickening
on CT and histological evidence of inflammation in some
of these endoscopic negative segments support the possibility
of mucosal or submucosal inflammation in the absence
of endoscopic mucosal lesions. By contrast, another study
observed that alterations in MRI findings were very rare in the
presence of a normal mucosa at endoscopy.30 In order for
transmural healing to become an accepted endpoint of
treatment, beneficial outcomes associated to transmural
healing should be clearly demonstrated. Most CD patients
have inflammatory disease at diagnosis and develop compli-
cated disease patterns as the disease evolves.57,58 A long term
therapeutic goal should be aimed at prevention of this pattern
of evolution. It would be of interest to determine the
differential predicting accuracy of transmural healing and
mucosal healing on disease progression. Both MRI and CT scan
are very useful techniques to detect transmural inflammation
and extraluminal complications. While the role of MRI and CT-
enteroclysis or enterography for the study of the small bowel
is well established in several studies, less is known about
assessment of colonic transmural pathology.30,59 Transab-
dominal US can also be used to detect bowel wall thickening,
to aid disease diagnosis and complication assessment.61–63 Its
contribution to clinical decision-making and its prognostic
role60,64 are relevant, provided that an expert operator is
available, as high inter-observer variation and lack of
standardization were historically attributed as limitations to
such technique.32,65 CT, US, and MRI have consistently been
shown to possess superior sensitivity and specificity compared
to conventional small bowel follow-through (SBFT) for the
detection of luminal lesions in proximal small bowel, providing
additional invaluable information on the presence of extra-
luminal complications.66–68 These facts, always keeping in
mind risks associated to radiation exposure,69–72 led to the
general recommendation of using cross-sectional imaging
modalities for the assessment of CD lesions in the more
proximal intestine and for assessment of stricturing
and penetrating complications. MRI or US should be used
wherever possible to limit radiation exposure. Future research
should be focused on standardization of the preparation,
technological aspects (protocols), and imaging criteria used to
assess CD lesions.
The use of labeled markers that reliably accumulate in
pathologically hypermetabolic cells associated with inflam-
mation is attractive for the diagnosis and follow-up assessment
of patient progress in CD, particularly to assess transmural
healing. It provides an addeddimension to investigations based
on structural changes associated with inflammation obtainedfrom CT or MRI enterography and US.32 Scintigraphy has not
been widely adopted mainly because the most sensitive and
specific method based on 99mTc-HMPAO (Tc-hexa methyl
propylene amine oxine) labeled white blood cells requires
extracorporeal labeling and more specific methods using
labeled antibodies to cytokines have still not been sufficiently
developed.32,73–76 Nonetheless scintigraphy, due to its rela-
tively low radiation exposure, was proposed as a useful
technique in the diagnostic workup of pediatric population
with suspected or known IBD.77–79 Accumulation of 18FDG in
hypermetabolic cells has relevant potential for IBD diagnosis
and monitoring, and may highlight active inflammation in CD
when using analysis of positrons emitted during 18F decay by
means of positron emission tomography (PET). Combining PET
withCT imagingenables localization of inflamed intestinewith
good spatial resolution.80–82 A strategy whereby initial
combined PET-CT imaging and PET alone as follow up to assess
healingmight have value83 since the radiationdose fromFDG is
relatively low. The recent introduction of PET-MRI may be an
elegantwayof reducing radiationexposureandallow repeated
assessment. However, it will probably take considerable time
before this technique becomes generally available.
Key messages:• Mucosal lesions should be considered as a standard for
assessment of disease evolution and therapeutic efficacy, until
the superiority of other measures of structural damage is shown
• Transmural healing in CD is a matter of growing interest, as the
disease is not purely mucosal. However reliable definitions of
transmural healing are not yet available.
• Many imaging techniques were validated for disease diagnosis
and for detection of disease activity [magnetic resonance (MRI)
or CT scanner entero-graphy/-clysis, bowel ultrasound (US),
scintigraphy, positron emission tomography (PET)-CT, single-
photon emission computed tomography (SPECT)], but none of
these techniques was validated for definition of transmural
healing
• Non irradiating techniques should be preferred, especially in
young patients
Areas for future research• Standardization of imaging techniques (US, MRI) and of alterna-
tive imaging (especially PET-CT/PET-MRI) with evaluation of
their performance with major prognostic goals set as outcomes
• Standardized definition of transmural healing
• Added value of transmural healing over mucosal healing and its
impact on long term evolution of CD.5. How to assess fistulae and strictures in Crohn's
disease (pathological healing)?
5.1. Stricturing disease
A high proportion of patients will develop strictures over the
course of CD. This is probably part of the healing process
in transmural inflammation, although very often, strictures
contain both fibrotic and inflammatory components.
489Imaging and biomarkers assessing intestinal healing in IBD5.2. Definition of stricture
The most reliable definition of a stricture is a localized,
persistent bowel narrowing whose functional effects may be
judged from prestenotic dilatation.84,85 However, various
definitions of strictures have been used in radiological studies,
including the presence of severe luminal narrowing in regions
of bowel wall thickening with or without prestenotic
dilatation.86
5.3. Radiological techniques for the detection of
strictures
Optimal CT or MRI assessment of intestinal wall abnormalities
requires luminal distension and systematic examination using
nonabsorbable oral contrast. CT or MRI enterography is
currently accepted as a preferable alternative to CT or MRI
enteroclysis, being as accurate and better tolerated.87 The
accuracy of both CT and MRI enterography or enteroclysis for
the detection of small bowel strictures is high.26,88–90 26,91–94
US has also shown high diagnostic accuracy for the detection
of small bowel strictures61–63,86,95 but the sensitivity of US
is lowest for those strictures located proximal small bowel
segments.
5.4. Comparison between radiological techniques
Direct comparison of CT and MR for the diagnosis of a variety
of small bowel lesions including IBD demonstrates similar
high sensitivities and specificities for both techniques.96
Studies that directly compared barium studies with MR
enterography or enteroclysis found no differences in the
detection of strictures but a more detailed characterization
with MRI.66,97,98 Strictures are potentially amenable to
surgical treatment, and cross-sectional techniques allow
better mapping and provide additional important informa-
tion such as the identification of potential inflammatory
masses or other associated complications (e.g., fistulas or
abscesses) and the identification of their relationships with
other structures. However, none of the aforementioned
studies comparing radiological techniques included an
accepted reference standard, and this is an important
limitation.
5.5. Differentiation between fibrotic and
inflammatory strictures
Theoretically, the presence of fibrotic obstruction favors
surgical treatment, but the frequently present overlap
between inflammation and fibrosis represents a difficulty
for decision making on the best treatment option. Bowel
thickening reflects both the presence of an inflammatory
component and fibrosis in deep layers. Hyperenhancement
and edema at CT and MRI may be more specific for
inflammation. One prospective study correlated the wall
echo pattern at US with histology after surgical resection.
The US stratified echo pattern (different echogenicities in
the different bowel layers) at the site of strictures may help
to detect collagen deposition.61 Fibrosis is usually seen as a
hyperechogenic band, in contrast with other layers of thebowel, conferring the stratified echo pattern. No published
study so far disclosed imaging parameters that can reliably
predict the response to therapy in the setting of stricturing
CD.
5.6. Penetrating disease
Penetrating CD, defined according to ECCO as the presence of
internal fistulas and/or abscesses, should be identified by
using diagnostic tools able to detect the mural and extramural
complications of the disease. For intra-abdominal penetrating
disease, CT/MRI enterography or enteroclysis and US are more
sensitive than standard barium examinations. Likewise, the
superiority of CT with respect to barium studies has been
confirmed in all published papers. To date, no studies have
specifically compared CT and MRI for imaging penetrating CD.
Only one study has compared US and MRI for assessing
extension and inflammatory activity in CD.99 In this study,
both techniques showed high diagnostic accuracy for the
diagnosis of CD and its penetrating complications, with fair
agreement between the two procedures.
The trials on the anti-TNF agents in fistulizing CD were
mainly focused on perianal disease. The main endpoint was a
greater than 50% reduction in the number of draining
fistulas. The complete resolution of drainage was a second-
ary end-point. These end-points were determined using the
Fistula Drainage Assessment Measure, which characterizes
fistulas as open (i.e. actively draining) if an investigator can
express purulent material from the fistula with the applica-
tion of gentle pressure to the tract. However, several reports
using either MRI or endoscopic ultrasound (EUS) to assess
perianal fistulae, have shown the persistence of active
fistulae even in absence of external drainage.24,25,100 These
findings were recently confirmed,101 showing that only 28%
of the 46% of CD patients considered in clinical remission
with anti-TNFs showed the healing of perianal fistulous track
at MRI. In concordance with the MRI findings, EUS showed
complete healing of the fistula track in only one third of the
patients with closure of external fistula.102 Persistence of
active fistula track at EUS examination103 was observed in
48% patients, 86% of whom presented the complete cessation
of drainage on the Fistula Drainage Assessment Measure. On
the basis of these observations, “deep healing” of fistulas
can be considered a relatively rare outcome. No study has
compared the diagnostic accuracy of MRI and EUS in defining
the activity of perianal fistulas in CD. MRI and EUS could be
considered useful tools for guiding treatment decisions (e.g.,
stopping anti-TNF, removing setons, etc.). Fistula tracts that
show initial improvement on MRI and/or EUS 12–14 weeks
after treatment have a good chance of remaining healed.
However, it is uncertain whether periodical imaging re-
evaluation regardless of the symptoms has a potential impact
on clinical management. On the basis of the most recent
evidence, the Fistula Drainage Assessment Measure should be
considered inadequate for defining fistula outcome during
and after therapy.
Key messages:
• MRI, and to a lower extent CT, due to radiation exposure, are
preferred techniques in order to assess the presence of strictures
• US is an adequate alternative when an expert operator is
available
490 M. Daperno et al.• No diagnostic tool is at present able to discriminate between
inflammatory and fibrotic component of strictures with certainty
• MRI is the preferred technique for detecting penetrating
complications of CD
• CT could be considered a suitable alternative only in case of
limited accessibility to MRI or in the emergency setting
• Bowel US, provided an expert operator is available, is accurate
and may serve as an alternative to other cross-sectional imaging
techniques for penetrating CD
• No cross-sectional imaging technique was validated to-date for
the assessment of internal fistulae and strictures healing in CD
• Tissue healing of perianal CD should be defined on the basis of
MRI (or EUS) findings, although none of the techniques was
evaluated for reproducibility
Areas for future research
• To explore the ability of cross-sectional imaging techniques to
predict therapeutic responses in CD, in stricturing and fistulizing
lesions
• To analyse the ability of cross-sectional imaging techniques to
highlight post-treatment changes in strictures and fistulae
predictive of different outcomes in the long-term follow-up.
6. Are serologic and genetic markers associated
with tissue healing?
In recent years strong emphasis has been placed on
identifying markers that can serve in facilitating diagnosis,
disease differentiation and prognosis. Biomarkers can be
divided into long-term markers (e.g., genetics and serology)
associated with clinical phenotype, and short-term markers,
associated with flares or tissue inflammation. As far as the
association with tissue healing concerns, genetic markers,
and probably also serologic markers, could be associated
rather with a tendency to real healing or to pathological
healing and subsequent complications (see above) than with
the presence of tissue healing at a given time point.
6.1. Genetic markers
The three common NOD2/CARD15 mutations were associated
with ileal disease and fibrostenosing behavior, suggesting an
inclination toward pathological healing.104,105 In a recent
study,106 a more complex genetic model was used including
both novel (e.g. ATG16L1, IL23R) and earlier (NOD2, IBD5 and
DLG5) genetic markers. In this study, patients with CD with a
more severe disease course, surgeries or an age of onset
below 40 years had more risk-alleles compared to non-
stricturing, non-penetrating behavior, no operations or age
at onset greater than 40 years, again suggesting an associ-
ation between these genetic variants and an inclination
towards an absence of tissue healing or a pathological
healing. However, the association became insignificant in
longer disease duration, confirming that many other factors
(e.g. clinical variables, disease phenotype at diagnosis,
medical therapy) contribute to the long term evolution of
disease phenotype. In an even more comprehensive study of
clinical, demographic, serological and genetic factors
associated with the development of complications, it was
shown that homozygosity for the rs1363670 G-allele in a gene
encoding a hypothetical protein near the IL12B gene wasindependently associated with stricturing disease behavior
and with shorter time to strictures, especially in patients
with ileal involvement.1076.2. Serologic markers
Serologic markers include ASCA, gASCA ALCA ACCA AMCA
anti-L and anti-C (the novel anti-glycan antibodies). Other
microorganism-directed antibodies include OmpC, CBir1, I2
and APLA.108 These may serve as tools for diagnosis, disease
stratification and prediction of disease phenotype or
progression. However, they are not able to predict tissue
healing or rapid changes in mucosal status. While levels of
serologic markers such as ASCA and the anti-glycan anti-
bodies may slightly fluctuate over time, it has been reported
that the dichotomous status of the markers (positive or
negative for a respective antibody) in IBD patients appears to
be widely stable in serial measurements in individual
patients. Between 74.2 and 89% of the CD patients and
83.7 to 97.8% of the UC patients remained in the same status
they had at the initial sample procurement.109,110 A large
body of information is available about seroreactivity to anti-
glycan markers and complicated disease behavior in
CD.108,111–114 Most information is derived from cross-sec-
tional studies with samples taken at various random points
during the disease course, combining serum taken before, at
the time of and after complications occurred. These studies
first performed with ASCA,115–117 then with single glycan
markers,110–113 including more recently anti-L and anti-C
antibodies,114 suggest an association between these markers
and stricturing and/or internal penetrating disease. To add
clinical value for these markers and really see whether they
can predict pathological healing, one has to go beyond
association studies and evaluate a predictive capacity of
serum markers in respect to the occurrence of complicated
CD-behavior and surgery. Limited information is available,
mainly from pediatric cohorts indicating an increased
likelihood for complicated disease courses with an increasing
immune response to microbial components. In a retrospec-
tive pediatric onset CD cohort it was shown that ASCA can
serve as a predictor for the earlier occurrence of complicat-
ed CD-behavior or surgery.118 The largest study to date using
a prospective study design indicates that an increasing
immune reactivity to ASCA, anti-cBir1 and anti-OmpC
indicated a faster progression towards complicated disease
and surgery.119 To date only one study is available assessing
the predictive use of anti-glycan antibodies in adult CD110: in
Fifty percent of cases sera were obtained within one year of
diagnosis. Positivity for the single markers ASCA, ACCA,
AMCA and anti-L, as well as an increasing number of positive
markers out of the whole panel independently indicated
faster progression towards a more complicated CD course,
defined as the occurrence of fistulas, strictures or CD-
related surgery. Even though this study was underpowered,
it nevertheless suggests a predictive value of the markers for
the natural history of CD, particularly a trend toward
pathological healing. Disease location seems to act as an
important confounder: serologic markers may not be
sensitive enough to be used in patients with isolated colonic
disease, since ASCA and gASCA, as well as several of the other
glycan markers are associated with ileal and small bowel
491Imaging and biomarkers assessing intestinal healing in IBDdisease location, and therefore negatively associated with
isolated colonic disease. Prospective studies with a complex
model including detailed disease phenotype and serology
profile are needed to analyze the complex effect of serology
on disease progression and long term tissue healing. In
contrast, over the short term, positivity for ASCA does not
seem to predict response, including tissue healing, to anti-
TNF or 5-ASA therapies.120,121 Finally, there is evidence from
other gastrointestinal diseases that the change in serologic
response may occur slowly. Most probably that is why only
little variation was reported in antibody titres in IBD. Strong
marker expression was observed for both ASCA122 and the
newly discovered glycan markers123 in celiac disease at the
time of diagnosis (ASCA 40–60%; any glycan marker positive
in 66%), especially in patients with severe malabsorption
(any glycans: 78%). However, the response was completely
lost after long-term (2–2.5 years) gluten-free diet. This
observation suggests that serologic markers might also
change and become negative in subgroups of IBD patients
who achieve long term complete mucosal healing, although
such an hypothesis will require prospective studies to be
assessed.
Key messages:
• Genetic markers are associated with the development of CD
complications and may possibly allow in the future prediction of
inability to heal or occurrence of pathological healing.
• Serologic markers do not fluctuate much and are not associated
with tissue healing over the short term, but they could also
predict inability to heal or occurrence of pathological healing.
Areas for future research:
• Confirm the predictive value of genetic and/or serologic markers
on the ability to heal and the pattern of tissue healing in IBD.
• Assess the capacity to decrease the risk of development of
complications in genetically or serologically-defined high risk
patients by various therapeutic strategies.
7. What is the role of stool markers in the
assessment of mucosal healing?
While a rather large number of studies have assessed the
correlation between fecal calprotectin and endoscopic
activity in CD, only few have tried to establish thresholds
for the prediction of mucosal healing and/or non significant
endoscopic lesions. In UC, even less studies have been
performed, probably because a simple sigmoidoscopy can
sufficiently provide an assessment of the situation for
decision making. Globally, four studies are available in
CD,11,124–126 two in mixed populations of CD and UC,127,128
and two in UC.129,130 In CD, only one of these studies included
a formal assessment of various thresholds for calprotectin to
determine the optimal cut-off for the prediction of mucosal
healing or non significant endoscopic activity.11 In a first CD
study, an abnormal value of calprotectin (N 50 μg/g) was
associated with the presence of endoscopically active
disease (SES-CDN7).124 In another study, fecal calprotec-
tinN200 μg/g could predict endoscopically active disease
(CDEIS≥3) with a sensitivity of 70% and a specificity of
92%.126 In a third study, at a threshold of 70 μg/g, the global
accuracy for the prediction of endoscopically active diseasewas 87%.125 In the fourth study (only published in an abstract
form), performed on 85 patients, several thresholds of
calprotectin were tested.11 The optimal threshold to detect
endoscopically inactive disease (CDEISb3) was 250 μg/g with
a sensitivity of 82% and specificity of 53%. In this study,
combining hsCRPb5 mg/l together with fecal calprotectin
improved the specificity to 72% while only slightly decreasing
sensitivity to 74%.
In UC, only 2 studies have evaluated the ability of fecal
calprotectin to predictmucosal healing.129,130 In one of these,
the overall accuracy for the detection of endoscopically active
disease (Rachmilewitz score ≥4) was 89%.129 This was
superior to blood biomarkers (CRP, white cells count) and
clinical activity index. In a pediatric studymixing 26 CD and 32
UC, PPV and NPV for the prediction of endoscopically active
diseasewere 81% and 87% respectively.127 In a third study, the
overall accuracy of fecal calprotectin for the prediction of
endoscopically active disease was around 80% both in UC and
CD.128 There is currently no published evidence-based answer
whether calprotectin has an added value over endoscopic
healing to predict disease outcome. However, the GETAID
STORI trial (only published in abstract form) suggests that
there may be an added value.11 In this study, approximately
30% of the patients with full mucosal healing experienced a
relapse of CDwithin one year after infliximab discontinuation.
By multivariate analysis, fecal calprotectin level as well as
high sensitivity CRP (hs-CRP) were found complementary to
endoscopic activity score and the combination of these
markers, together with some clinical characteristics allowed
the identification of a subgroup of patientswith a very low risk
of relapse (around 10% over one year).
As far as the type of fecal marker, there is no evidence-
based answer. Fecal calprotectin has been the most widely
studied. Fecal lactoferrin seems to be generally as good as
calprotectin to predict endoscopic activity of the dis-
ease124,126,131,132 and might be better than calprotectin for
assessing ileal disease activity.133 S100A12 is another member
of S100 family in addition to calprotectin (S100A8/S100A9). It
has been studied only in a small series of patients with IBD and
has been suggested to be more sensitive than fecal calpro-
tectin134 but this needs further validation. No studies have
correlated S100A12 with endoscopic activity of CD or UC. Day-
to-day variation of fecal markers has been inadequately
studied.135 As far as the optimal threshold of these fecal
markers, there is currently no evidence-based answer either.
However, it is obvious from studies correlating calprotectin to
endoscopic activity scores, that no universal threshold can
have a 100% accuracy. Particularly, approximately 15–20% of
patients in full mucosal healing still have elevated fecal
calprotectin levels, while approximately the same proportions
of patients with significant endoscopic lesions have calprotec-
tin level within the normal range.126 What we currently do not
know is if these “out of range” values reflect a particular stable
biological trait in those patients and hence could be used as an
individual threshold. Longitudinal measures and clinical follow
up are needed to answer this important question.
Key messages:
• Calprotectin and other stool markers significantly correlate with
endoscopic scores of activity and may become in the near future
an alternative or surrogate marker of mucosal healing, at least
for Crohn's colitis and ulcerative colitis.
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healing still needs confirmation from large prospective studies.
Areas for future research:
• Comparisons of various fecal markers and longitudinal follow up
of stool markers aiming at clarifying whether clinically mean-
ingful thresholds can be identified.
• Optimal stool markers for different disease locations and
behaviors should be studied.
8. What is the role of blood markers in the
assessment of mucosal healing?
Very few studies have assessed the correlation between
blood markers and objective measurement of disease
activity in the gut in inflammatory bowel disease. The
marker which has been most broadly studied is CRP, and in
the few studies where CRP was compared to other blood
markers, such as inflammatory cytokines, cytokine receptors
or other acute phase reactants, those were usually not found
consistently superior.3,108,124 In CD, circulating CRP levels
were not found to correlate closely with endoscopic
activity.136 Particularly, the correlation between endoscopic
index of severity (CDEIS) and CRP resulted statistically
significant but very weak.3,108,127 Still, an elevated CRP
may increase the likelihood of presenting endoscopic
lesions.137 In UC, blood markers are less useful except for
extensive disease138 and fecal markers seem to be more
appropriate for prediction of endoscopic activity 139. This
was confirmed in a recent Japanese study where the
association between CRP and endoscopic activity was
significant only for extensive but not for distal UC.138 In a
large transversal study including 164 CD patients, hs-CRP and
IL-6 blood concentrations showed a similar correlation with
endoscopic score of activity. The areas under the ROC-curve
with these markers were between 70 and 80%.124 No
systematic search for optimal threshold of CRP in predicting
mucosal healing in CD has been performed yet. In a recent
study, the sensitivity and specificity of hs-CRPb5 mg/l to
predict the absence of significant endoscopic activity of the
disease (CDEISb3) were 78% and 39%, respectively. These
values were lower than for fecal calprotectin, but the
combination of these 2 markers gave the best results.11 The
proposal to use hs-CRP came from the cardiovascular
research in order to predict evolution in coronary heart
disease. Since in cardiovascular disease normal methods for
CRP measurement are not sensitive enough, a hs-CRP assay
has been developed and is currently in use helping to predict
the first or recurrent coronary events.140 At this moment
there is no evidence that measuring hs-CRP yields better
results than conventional CRP measurement in IBD patients.
Moreover another cheaper assay, the wide range CRP,
measures concentrations ranging from 0.05 to 160 mg/l and
yields results that correlate closely with those of hs-CRP
detection kits. CD is usually a transmural disease, therefore
it is probable that beside fecal markers, blood markers will
be necessary to better reflect the whole pathology process.
Here again, a correlation with transmural inflammation has
been essentially shown with CRP. In a large retrospective
study correlating endoscopic appearance of the terminalileum, CT enterography features and CRP, a significant
correlation was found between CRP and perienteric inflam-
mation (increased fat density) but not with the intensity of the
inflammation limited to the small bowel wall.141 Regarding
newer bloodmarkers such as procalcitonin, phagocyte-specific
S100 proteins, neutrophil gelatinase-associated lipocalin
(NGAL) or ghrelin, no information is available concerning
their correlation to mucosal or tissue inflammation. As we
know from clinical practice and from clinical studies, an
important percentage of patients with IBD do have normal
indices of inflammation even in the presence of active disease.
In order to identify markers relevant for each individual
patient, it may be helpful in the future to assess a panel of
potential markers to select, for each patient, the one which is
best correlated with mucosal and tissue inflammation.
Key messages:
• In Crohn's disease, CRP may be a weak surrogate marker of
mucosal healing.
• In extensive ulcerative colitis, a significant correlation between
endoscopic disease activity and CRP values was shown.
• At this moment there is no evidence that measuring high
sensitivity CRP yields better results than conventional CRP in
IBD patients, included in the prediction of mucosal healing.
Areas for future research:
• Prospective analysis of correlations between CRP drop and
mucosal healing.
• Study of new blood markers better correlated to gut
inflammation.
• Analysis of the clinical impact of serial measurements of
combination of blood markers.
9. Are there alternative biomarkers of interest?
Tissue factors mediating the inflammation in IBD are
potential biomarkers for both prediction and monitoring of
the clinical course of IBD and of response to therapy,
including tissue healing. From a theoretical point of view,
mucosal markers should be better predictors than serolog-
ical, fecal or urine markers as long as the main inflammatory
events are located in the inflamed mucosa. However, up to
now no mucosal marker has been significantly associated
with mucosal healing or to disease severity. For the large
majority of the possible analyses, the rigorous sampling
procedure required is not suited for daily clinical activity. Of
the few exceptions are the samples for quantitative gene
expression analyses using transport medium at room tem-
perature for at least one week without degradation of
RNA.142 Nevertheless, the introduction of new mucosal
markers for clinical use represents a great logistic challenge
from biopsy sampling to the final step of analyses.
There are no reports which demonstrate that mucosal
expression of TNF-α predicts clinical course and only few
reports exist regarding the predictive value of mucosal
TNF-α on response to treatment. Pretreatment mucosal
TNF-α was negatively correlated to response to infliximab in
CD143 and in UC.144 This disagrees with another report where
low expressions of TNF-α predicted poor response to therapy
in CD.(145) Higher levels of TNF-α were also observed in
corticosteroid non-responders than in responders to steroids
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study.147 Of interest is the microarray/RT-PCR study of Arijs
and colleagues in which gene expression associated with non
response to infliximab in UC was tested.148 TNF-receptor
(SF11B) predicted the clinical response. Other predictors
were the glycoprotein STC1 maintaining the endothelial
permeability, the tissue injury factor cyclooxygenase 2b
molecule PTGS2 linked to the biosynthesis of prostaglandin,
and finally the receptor for the proinflammatory cytokine
interleukin-13 (IL-13-R) and the anti-inflammatory cytokine
IL-11.
At present it is merely an optimistic thought, although
logically attractive, that integration of serologic and stool
markers with mucosal markers may increase reliability of the
prediction of mucosal healing. New metabolomics tech-
niques such as NMR spectroscopy of fecal extracts have
demonstrated differences in metabolic profiles in IBD
compared to healthy controls.149 Moreover, in a mapping
analyses of urinary metalloproteinases (MMPs) performed by
Manfredi et al., MMP-2 and MMP-9/NGAL were independent
predictors of CD and UC.150 This opens the possibility for
new non-invasive fingerprinting methods but its potential
as a prognostic biomarker is unknown.149 Moreover, urine
markers represent a promising tool as the collection of urine
samples is easy to perform and non-invasive. The parame-
ters are mostly expressed as ratio to creatinine and
therefore the more complicated sampling of 24 h urines is
unnecessary.
Key messages:
• Molecular analysis of tissue samples is a promising approach, but
problems with logistics, costs and technical complexity limit at
present its current use.
• Urinary markers, chemokines, cytokines, cellular mediators and
adhesion molecules may represent interesting candidates as
alternative biomarkers.
• At present no alternative biomarker was formally tested for the
evaluation of tissue healing and therefore such techniques are
still not suitable for use outside of clinical trials.
• At present the only marker with some clinical relevance seems to
be TNF-α expression, although its clinical relevance is still
limited.
Areas for future research:
• Prospective studies with a broad fingerprinting assay from
mucosa and body fluids aiming at identification of correlations
with mucosal pattern and/or clinical outcomes.
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